Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMY) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 3,490,000 shares, a growth of 151.1% from the September 30th total of 1,390,000 shares. Based on an average daily volume of 5,470,000 shares, the short-interest ratio is presently 0.6 days. Currently, 10.9% of the company’s shares are sold short. Currently, 10.9% of the company’s shares are sold short. Based on an average daily volume of 5,470,000 shares, the short-interest ratio is presently 0.6 days.

Femasys Trading Up 2.5%

Shares of FEMY stock opened at $0.64 on Friday. The company has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.79. Femasys has a 1-year low of $0.31 and a 1-year high of $1.80. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.89 and a quick ratio of 0.41. The firm has a market cap of $20.76 million, a PE ratio of -0.74 and a beta of -2.64.

Femasys (NASDAQ:FEMY) last posted its earnings results on Friday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.80 million. Femasys had a negative return on equity of 713.74% and a negative net margin of 1,113.72%. On average, analysts predict that Femasys will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. acquired a new position in shares of Femasys in the second quarter valued at approximately $45,000. Jane Street Group LLC acquired a new position in shares of Femasys in the second quarter valued at approximately $82,000. Clear Creek Financial Management LLC grew its holdings in shares of Femasys by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 281,821 shares of the company’s stock valued at $272,000 after purchasing an additional 11,450 shares in the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in shares of Femasys in the first quarter valued at approximately $1,969,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright reduced their target price on shares of Femasys from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Wall Street Zen raised shares of Femasys to a “sell” rating in a research note on Saturday, October 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Femasys in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.